Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05912387 · ClinicalTrials.gov registry record · Early Phase 1

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

A Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis, sponsored by Stanford University.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT05912387 is a Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Stanford University. The registered enrollment target is 15 participants, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05912387, a Early Phase 1 study of Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model

Interventions

  • DRUG Rosuvastatin

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-05-31
Est. Completion 2027-12-31
Phase Early Phase 1

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT05912387

The ClinicalTrials.gov registry entry for NCT05912387 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42,261-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 1 intervention - of which Rosuvastatin is the first listed.

NCT05912387 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05912387 about?

NCT05912387 is a clinical study titled "Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study". PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The invest...

What is the current status of trial NCT05912387?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2023-05-31. Estimated completion is 2027-12-31.

What conditions does trial NCT05912387 study?

This clinical trial studies the following conditions: Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis.

What interventions are being tested in trial NCT05912387?

The interventions under investigation include: Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT05912387?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05912387 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Bowel Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.